.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates in the Management of Hairy Cell Leukemia

EP. 1: Introduction and Epidemiology of Hairy Cell Leukemia

June 30th 2020

EP. 2: Molecular Genetic Changes for Hairy Cell Leukemia

June 30th 2020

EP. 3: Signs and Tests for Diagnosis and Prognosis of HCL

June 30th 2020

EP. 4: Differential Diagnosis and Molecular Tests in Identifying HCL

June 30th 2020

EP. 5: Determining When to Treat and First-Line Therapy for HCL

June 30th 2020

EP. 6: Combination First-line Therapy in Hairy Cell Leukemia

June 30th 2020

EP. 7: When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

June 30th 2020

EP. 8: Historical Treatment for Relapsed/Refractory HCL

June 30th 2020

EP. 9: Landscape Change in the Treatment of Relapsed/Refractory HCL

June 30th 2020

EP. 10: The Role of CD22-targeted Immunotoxins in HCL

June 30th 2020

EP. 11: Treatments for Relapsed/Refractory HCL in Pipeline

June 30th 2020

EP. 12: Advice for Community Oncologists on Treating HCL

June 30th 2020